Overview

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

Status:
RECRUITING
Trial end date:
2030-01-07
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborator:
Hebei Taihe Chunyu Biotechnology Co., Ltd